<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30425844</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>16</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">2059-7029</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>3</Volume>                    <Issue>6</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>ESMO open</Title>                <ISOAbbreviation>ESMO Open</ISOAbbreviation>            </Journal>            <ArticleTitle>Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.</ArticleTitle>            <Pagination>                <MedlinePgn>e000440</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1136/esmoopen-2018-000440</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Patients with metastatic human epidermal growth factor receptor 2-positive breast cancer (HER2+ BC) frequently experience brain metastases (BM). We aimed to define risk factors for the development of BM in patients with HER2+ BC and to report on their outcome.</AbstractText>                <AbstractText Label="Methods" NlmCategory="UNASSIGNED">This is a retrospective analysis of patients diagnosed with HER2+ BC between January 2000 and December 2014 at Institut Jules Bordet, Belgium. Statistical analyses were conducted with SAS V.9.4 using Kaplan-Meier method and Cox regression analyses.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 483 patients were included of whom 108 (22.4%) developed metastases and 52 (10.8%) BM. Among 96 metastatic patients without BM at diagnosis, 40 (41.7%) developed BM in the course of their disease. In multivariate analysis, risk factors for the development of BM were age ≤40 years (HR 2.10, 95 % CI 1.02 to 4.36), tumour size &gt;2 cm (HR 4.94, 95% CI 1.69 to 14.47), nodal involvement (HR 3.48, 95% CI 1.47 to 8.25), absence or late start (≥6 months after initial diagnosis) of adjuvant anti-HER2 treatment (HR 3.79, 95% CI 1.52 to 9.43 or HR 2.65, 95% CI 1.03 to 6.82) and the development of lung metastases as first site of relapse (HR 6.97, 95% CI 3.41 to 14.24). Twenty-two patients with HER2+ BC and BM sent to our institute for further treatment were included in the outcome analysis. Asymptomatic patients at the time of BM diagnosis showed a better overall survival than symptomatic patients (HR 0.49, 95% CI 0.25 to 0.94).</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">A considerable number of patients with metastatic HER2+ BC will develop BM. Screening of patients with risk factors for BM might lead to early detection and better outcome. However, randomised controlled trials examining the use of MRI as a screening method for BM in patients with metastatic BC are warranted before such an approach can be recommended.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Maurer</LastName>                    <ForeName>Christian</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tulpin</LastName>                    <ForeName>Lorraine</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Moreau</LastName>                    <ForeName>Michel</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Unité de Gestion de l'Information, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dumitrescu</LastName>                    <ForeName>Cristina</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Medical Oncology Clinic, Charleroi Universitary Hospital, Université Libre de Bruxelles (U.L.B.), Charleroi, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>de Azambuja</LastName>                    <ForeName>Evandro</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Paesmans</LastName>                    <ForeName>Marianne</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Unité de Gestion de l'Information, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nogaret</LastName>                    <ForeName>Jean-Marie</ForeName>                    <Initials>JM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Piccart</LastName>                    <ForeName>Martine J</ForeName>                    <Initials>MJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Awada</LastName>                    <ForeName>Ahmad</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>24</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>ESMO Open</MedlineTA>            <NlmUniqueID>101690685</NlmUniqueID>            <ISSNLinking>2059-7029</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Apr 24;14:289</RefSource>                <PMID Version="1">24761771</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1999 May;17(5):1474-81</RefSource>                <PMID Version="1">10334533</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2006 Jun;17(6):935-44</RefSource>                <PMID Version="1">16603601</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2012 Nov;136(1):153-60</RefSource>                <PMID Version="1">22968656</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1992 Jul;10(7):1049-56</RefSource>                <PMID Version="1">1351538</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2011 Jul;22(7):1571-81</RefSource>                <PMID Version="1">21059640</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Pract Radiat Oncol. 2012 Jul-Sep;2(3):210-225</RefSource>                <PMID Version="1">25925626</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Oncol (R Coll Radiol). 2004 Aug;16(5):345-9</RefSource>                <PMID Version="1">15341438</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2006 Aug 15;107(4):696-704</RefSource>                <PMID Version="1">16826579</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2007 Jul;12(7):766-73</RefSource>                <PMID Version="1">17673608</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1989 Aug;7(8):1120-8</RefSource>                <PMID Version="1">2569032</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2004 Jul 15;22(14):2865-72</RefSource>                <PMID Version="1">15254054</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Apr 20;28(12):2032-7</RefSource>                <PMID Version="1">20308667</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2009 Mar 24;100(6):894-900</RefSource>                <PMID Version="1">19240719</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2004 Nov;15(11):1640-4</RefSource>                <PMID Version="1">15520065</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 1989 May 12;244(4905):707-12</RefSource>                <PMID Version="1">2470152</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Science. 1987 Jan 9;235(4785):177-82</RefSource>                <PMID Version="1">3798106</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2007 Mar 15;13(6):1648-55</RefSource>                <PMID Version="1">17363517</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 Jan 1;25(1):118-45</RefSource>                <PMID Version="1">17159189</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):810-7</RefSource>                <PMID Version="1">12377333</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2003 Jul;14(7):1072-7</RefSource>                <PMID Version="1">12853349</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2004 May 22;363(9422):1665-72</RefSource>                <PMID Version="1">15158627</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Mar 1;31(7):961-5</RefSource>                <PMID Version="1">23129741</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2008;10(1):R20</RefSource>                <PMID Version="1">18307763</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2016 Feb;25:22-6</RefSource>                <PMID Version="1">26801412</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cochrane Database Syst Rev. 2012 Apr 18;(4):CD006243</RefSource>                <PMID Version="1">22513938</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast. 2006 Apr;15(2):219-25</RefSource>                <PMID Version="1">16026983</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Jul 10;28(20):3271-7</RefSource>                <PMID Version="1">20498394</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2011;6(6):e21030</RefSource>                <PMID Version="1">21695277</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2008 Jul;19(7):1242-8</RefSource>                <PMID Version="1">18334512</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Dec 10;26(35):5697-704</RefSource>                <PMID Version="1">19001334</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2009 Sep;117(2):297-303</RefSource>                <PMID Version="1">19130219</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource>                <PMID Version="1">24101045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Jul 1;32(19):2100-8</RefSource>                <PMID Version="1">24799487</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">HER2-positive breast cancer</Keyword>            <Keyword MajorTopicYN="N">brain metastases</Keyword>            <Keyword MajorTopicYN="N">risk factors</Keyword>        </KeywordList>        <CoiStatement>Competing interests: MJP declares the following competing of interest: she has served as a consultant for Roche outside the submitted work. EdA declares the following competing of interests: he has received research grants and travel grants from Roche and served on an advisory board of Roche outside the submitted work. CM declares that he has received travel grants form Mundipharma and Amgen outside the submitted work. All other authors declare no competing interests.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>13</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>15</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30425844</ArticleId>            <ArticleId IdType="doi">10.1136/esmoopen-2018-000440</ArticleId>            <ArticleId IdType="pii">esmoopen-2018-000440</ArticleId>            <ArticleId IdType="pmc">PMC6212674</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>